Dare Bioscience financials
$0.8150+8.67%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $9.8K | $2.8M | $10.0M | $0.00 | — | — | — | — |
| Gross profit | $734.4K | $9.8K | $2.8M | $10.0M | $0.00 | — | — | — | — |
| Gross margin | 71.3% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating income | -$13.6M | -$23.5M | -$30.9M | -$31.4M | -$39.1M | -$27.4M | -$14.3M | -$16.9M | -$11.2M |
| Net income | -$13.4M | -$4.1M | -$30.2M | -$30.9M | -$38.7M | -$27.4M | -$15.1M | -$16.7M | -$11.5M |
| Net margin | −1300.7% | −41430.9% | −1074.2% | −309.5% | — | — | — | — | — |
| Diluted EPS | $-1.20 | $-0.48 | $-4.15 | $-4.44 | $-7.56 | $-10.92 | $-11.64 | $-18.84 | $-42.72 |
| EBITDA | -$11.9M | -$23.4M | -$30.9M | -$31.4M | -$39.0M | -$27.4M | -$14.3M | -$11.7M | -$3.7M |
| Operating cash flow | -$9.9M | $5.5M | -$38.9M | -$18.1M | -$28.8M | -$25.2M | -$13.3M | -$10.3M | -$2.5M |
| Free cash flow | -$10.3M | $4.9M | -$39.5M | -$18.2M | -$28.8M | -$25.3M | -$13.3M | -$10.3M | -$2.5M |
| Diluted shares | 11.2M | 8.5M | 7.3M | 7.0M | 5.1M | 2.5M | 1.3M | 0.9M | 0.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.7M | $15.7M | $10.5M | $34.7M | $51.7M | $4.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $1.5M | $0.00 | $0.00 | $0.00 | $0.00 | $367.3K |
| Total assets | $32.5M | $22.1M | $21.3M | $43.8M | $55.8M | $7.6M |
| Total liabilities | $29.6M | $28.1M | $26.3M | $32.7M | $17.1M | $8.7M |
| Shareholders' equity | $2.8M | -$6.0M | -$5.0M | $11.1M | $38.8M | -$1.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology